CureVac N.V. (5CV.F)

EUR 3.15

(-2.48%)

Revenue Summary of CureVac N.V.

CureVac N.V.'s latest annual revenue in 2023 was 53.75 Million EUR , down -21.9% from previous year.
CureVac N.V.'s latest quarterly revenue in 2024 Q2 was 14.5 Million EUR , up 16.67% from previous quarter.
CureVac N.V. reported a annual revenue of 67.42 Million EUR in annual revenue 2022, down -34.54% from previous year.
CureVac N.V. reported a annual revenue of 102.99 Million EUR in annual revenue 2021, up 110.61% from previous year.
CureVac N.V. reported a quarterly revenue of 12.37 Million EUR for 2024 Q1, down -43.73% from previous quarter.
CureVac N.V. reported a quarterly revenue of 7.57 Million EUR for 2023 Q2, up 6.31% from previous quarter.

Annual Revenue Chart of CureVac N.V. (2023 - 2018)

Historical Annual Revenue of CureVac N.V. (2023 - 2018)

Year	Revenue	Revenue Growth
2023	53.75 Million EUR	-21.9%
2022	67.42 Million EUR	-34.54%
2021	102.99 Million EUR	110.61%
2020	48.9 Million EUR	180.78%
2019	17.41 Million EUR	35.31%
2018	12.87 Million EUR	0.0%

Year	Revenue	Revenue Growth
2024 Q2	14.5 Million EUR	16.67%
2024 Q1	12.37 Million EUR	-43.73%
2023 Q2	7.57 Million EUR	6.31%
2023 FY	52.65 Million EUR	-21.9%
2023 Q1	7.12 Million EUR	-39.01%
2023 Q4	21.98 Million EUR	33.4%
2023 Q3	16.48 Million EUR	117.48%
2022 Q3	11.21 Million EUR	-44.35%
2022 Q2	20.14 Million EUR	-17.34%
2022 Q1	24.37 Million EUR	-40.88%
2022 FY	67.42 Million EUR	-34.54%
2022 Q4	11.68 Million EUR	4.25%
2021 Q1	10.03 Million EUR	67.17%
2021 Q3	29.34 Million EUR	31.01%
2021 Q2	22.39 Million EUR	123.28%
2021 FY	102.99 Million EUR	110.61%
2021 Q4	41.22 Million EUR	40.51%
2020 Q4	6 Million EUR	16.23%
2020 Q3	5.16 Million EUR	-85.06%
2020 Q2	34.54 Million EUR	1007.69%
2020 Q1	3.11 Million EUR	-54.24%
2020 FY	48.9 Million EUR	180.78%
2019 Q1	3.15 Million EUR	0.0%
2019 Q3	1.09 Million EUR	0.0%
2019 FY	17.41 Million EUR	35.31%
2019 Q4	6.81 Million EUR	521.9%
2018 FY	12.87 Million EUR	0.0%

Peer Revenue Comparison of CureVac N.V.

Name	Revenue	Revenue Difference
BioNTech SE	3.81 Billion EUR	98.592%
Biotest Aktiengesellschaft	684.6 Million EUR	92.148%
Biotest Aktiengesellschaft	684.6 Million EUR	92.148%
BRAIN Biotech AG	55.33 Million EUR	2.85%
Formycon AG	77.69 Million EUR	30.81%
Heidelberg Pharma AG	9.85 Million EUR	-445.273%
Medigene AG	6.03 Million EUR	-790.918%